UY29581A1 - (5z)-5-(6-quinoxalinilmetilideno)-2-((2,6-diclorofenil)amino)-1,3-tiazol-4(5h)-ona - Google Patents

(5z)-5-(6-quinoxalinilmetilideno)-2-((2,6-diclorofenil)amino)-1,3-tiazol-4(5h)-ona

Info

Publication number
UY29581A1
UY29581A1 UY29581A UY29581A UY29581A1 UY 29581 A1 UY29581 A1 UY 29581A1 UY 29581 A UY29581 A UY 29581A UY 29581 A UY29581 A UY 29581A UY 29581 A1 UY29581 A1 UY 29581A1
Authority
UY
Uruguay
Prior art keywords
amino
compound
quinoxalinylmetilidene
diclorophenyl
tiazol
Prior art date
Application number
UY29581A
Other languages
English (en)
Inventor
Kevin J Duffy
Duke M Fitch
Beth A Norton
Original Assignee
Smithkline Beckman Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beckman Corp filed Critical Smithkline Beckman Corp
Publication of UY29581A1 publication Critical patent/UY29581A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

Es un objeto de la invención el compueto (5Z)-(6-quinoxalinilmetilideno)-2-((2,6-diclorofenil)amino)-1,3-tiazol-4(5H)-ona, y/o sales, hidratos, solvatos y profármacos farmacéuticamente aceptables de dicho compuesto. También es un objeto de la invención composiciones farmacéuticas que contienen este compuesto, métodos para preprar este compuesto y sales,hidratos, solvatos y profármacos farmacéuticamente aceptables del mismo. También es un objeto de la invención métodos para usar este compuesto como inhibidor de proteínas hYAK3.
UY29581A 2005-06-08 2006-06-07 (5z)-5-(6-quinoxalinilmetilideno)-2-((2,6-diclorofenil)amino)-1,3-tiazol-4(5h)-ona UY29581A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US68867105P 2005-06-08 2005-06-08

Publications (1)

Publication Number Publication Date
UY29581A1 true UY29581A1 (es) 2006-11-30

Family

ID=37532819

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29581A UY29581A1 (es) 2005-06-08 2006-06-07 (5z)-5-(6-quinoxalinilmetilideno)-2-((2,6-diclorofenil)amino)-1,3-tiazol-4(5h)-ona

Country Status (21)

Country Link
US (1) US7674792B2 (es)
EP (1) EP1888531A4 (es)
JP (1) JP2008543770A (es)
KR (1) KR20080014017A (es)
CN (1) CN101193863A (es)
AP (1) AP2007004241A0 (es)
AR (1) AR054059A1 (es)
AU (1) AU2006258032A1 (es)
BR (1) BRPI0611096A2 (es)
CA (1) CA2611480A1 (es)
EA (1) EA200702457A1 (es)
IL (1) IL187423A0 (es)
MA (1) MA29567B1 (es)
MX (1) MX2007015572A (es)
NO (1) NO20080130L (es)
NZ (1) NZ563421A (es)
PE (1) PE20070083A1 (es)
TW (1) TW200716580A (es)
UY (1) UY29581A1 (es)
WO (1) WO2006135712A2 (es)
ZA (1) ZA200709813B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1888557A4 (en) * 2005-06-08 2012-02-15 Glaxosmithkline Llc (5Z) -5- (6-QUINOXALINYLMETHYLIDENE) -2-Ý (2,4,6-trichlorophenyl) amino-1,3-thiazol-4 (5H) -one
US20100286041A1 (en) * 2007-03-22 2010-11-11 Smithkline Beecham Corporation (5z)-5-(6-quinoxalinylmethylidene)-2-[(2,6-dichlorophenyl)amino]-1,3-thiazol-4(5h)-one
WO2008150837A1 (en) * 2007-06-01 2008-12-11 Smithkline Beecham Corporation Methods of treatment

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5545648A (en) 1978-09-29 1980-03-31 Teikoku Hormone Mfg Co Ltd 2-formyldibenzazepin derivative and its preparation
US5089516A (en) 1987-03-11 1992-02-18 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha 1-phenyl-3,5-pyrazolidinedione hydroxystyrene compounds which have tyrosine kinase inhibiting activity
US4971996A (en) 1987-03-11 1990-11-20 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds which are useful as tyrosine kinase inhibitors
US5202341A (en) 1987-03-11 1993-04-13 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Hydroxystyrene compounds having tyrosine kinase inhibiting activity
JPH0197926A (ja) 1987-10-09 1989-04-17 Idemitsu Kosan Co Ltd 有機非線型光学材料
DD270072A1 (de) 1988-03-14 1989-07-19 Univ Halle Wittenberg Verfahren zur herstellung von 5-aryliden- hoch 2-thiazolin-4-onen
US5306822A (en) 1988-05-25 1994-04-26 Warner-Lambert Company Arylmethylenyl derivatives of oxazolidinone
US5145753A (en) 1989-09-12 1992-09-08 Mitsubishi Jukogyo Kabushiki Kaisha Solid electrolyte fuel cell
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
GB9004483D0 (en) 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
US5143928A (en) 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
JPH052200A (ja) 1990-09-28 1993-01-08 Toshiba Corp 有機非線形光学材料
DE69318863T2 (de) 1992-02-03 1998-09-24 Fuji Photo Film Co Ltd Verfahren zur Dispergierung eines Farbstoffs und ein Farbstoff enthaltendes photographisches Silberhalogenidmaterial
JP2835246B2 (ja) 1992-06-02 1998-12-14 富士写真フイルム株式会社 ハロゲン化銀写真感光材料
ZA936492B (en) 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
DE69331891T2 (de) 1992-09-11 2002-10-31 Agfa Gevaert Nv Photographisches Element,das einen Filterfarbstoff enthält, für Schnellverarbeitungs-Verwendungen
DE69333314D1 (de) 1992-09-11 2004-01-08 Agfa Gevaert Nv Photographisches Element,das einen Filterfarbstoff enthält, für Schnellverarbeitungs-Verwendungen
JPH06128234A (ja) 1992-10-19 1994-05-10 Fuji Photo Film Co Ltd 不斉炭素原子を有する化合物およびそれからなる非線形光学材料
US5554767A (en) 1993-05-21 1996-09-10 Warner-Lambert Company Alpha-mercaptoacrylic acid derivatives having calpain inhibitory activity
US6251928B1 (en) 1994-03-16 2001-06-26 Eli Lilly And Company Treatment of alzheimer's disease employing inhibitors of cathepsin D
EP0687573A1 (en) 1994-06-13 1995-12-20 Agfa-Gevaert N.V. Dye donor element for use in a thermal dye transfer method
JP3871354B2 (ja) 1994-07-29 2007-01-24 株式会社フジモト・コーポレーション 新規な２−（ｎ−シアノイミノ）チアゾリジン−４−オン誘導体
JPH08109176A (ja) 1994-10-07 1996-04-30 Torii Yakuhin Kk イソローダニンｎ酢酸誘導体
IL117208A0 (en) 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
US5618835A (en) 1996-02-01 1997-04-08 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
JPH09255669A (ja) 1996-03-22 1997-09-30 Hisamitsu Pharmaceut Co Inc 新規なベンジリデン誘導体
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6632947B2 (en) 1997-02-18 2003-10-14 Smithkline Beecham Plc Process for the preparation of substituted thiazolidinedione
US6011031A (en) 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
WO1999059586A1 (en) 1998-05-19 1999-11-25 Regents Of The University Of California Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
AU6330999A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
US6221613B1 (en) 1998-12-31 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding a human melanin concentrating hormone receptor (MCH1) and uses thereof
US6689491B1 (en) 1999-02-08 2004-02-10 Fuji Photo Film Co., Ltd. Luminescent device material, luminescent device using the same, and amine compound
US6372742B1 (en) 1999-07-01 2002-04-16 Geron Corporation Substituted indole compounds and methods of their use
JP2001072592A (ja) 1999-07-01 2001-03-21 Kyowa Hakko Kogyo Co Ltd テロメラーゼ阻害剤
US6720345B1 (en) 1999-11-05 2004-04-13 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
US7005288B1 (en) * 1999-11-10 2006-02-28 Novozymes A/S Fungamyl-like alpha-amylase variants
JP2001348520A (ja) 2000-04-03 2001-12-18 Fuji Photo Film Co Ltd メチン化合物、固体微粒子分散物、インクジェット用記録液、およびインクジェット記録方法
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP2004504303A (ja) 2000-07-05 2004-02-12 シナプティック・ファーマスーティカル・コーポレーション 選択的メラニン凝集ホルモン−１（ｍｃｈ１）受容体アンタゴニストおよびその使用
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
DE10115227A1 (de) 2001-03-28 2002-12-19 Bayer Ag Optischer Datenträger enthaltend in der Informationsschicht eine lichtabsorbierende Verbindung mit mehreren chromophoren Zentren
US6452014B1 (en) 2000-12-22 2002-09-17 Geron Corporation Telomerase inhibitors and methods of their use
JP2004526756A (ja) 2001-04-06 2004-09-02 スミスクライン ビーチャム コーポレーション ｈＹＡＫ１及びｈＹＡＫ３キナーゼのキノリン阻害剤
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US20050019825A9 (en) 2002-03-15 2005-01-27 Qing Dong Common ligand mimics: pseudothiohydantoins
US7482455B2 (en) 2002-10-16 2009-01-27 Smithkline Beecham Corporation Chemical compounds
PT1567112E (pt) 2002-11-22 2009-01-08 Smithkline Beecham Corp Novos compostos químicos
US7645421B2 (en) * 2003-06-20 2010-01-12 Roche Diagnostics Operations, Inc. System and method for coding information on a biosensor test strip
US8106214B2 (en) 2003-07-28 2012-01-31 Merck Serono Sa 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors
US20050042213A1 (en) 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
EP1718297A4 (en) 2004-01-09 2009-09-02 Smithkline Beecham Corp NEW CHEMICAL COMPOUNDS
JP2007520558A (ja) 2004-02-04 2007-07-26 スミスクライン・ビーチャム・コーポレイション キナーゼ阻害剤として有用なピリミジノン化合物
WO2005082363A1 (en) 2004-02-20 2005-09-09 Board Of Regents, The University Of Texas System Thiazolone compounds for treatment of cancer
WO2005082901A1 (en) 2004-02-25 2005-09-09 Smithkline Beecham Corporation Novel chemical compounds
AU2005259512A1 (en) 2004-07-01 2006-01-12 F. Hoffmann-La Roche Ag Thiazolinone unsubstituted quinolines
ES2317238T3 (es) 2004-07-01 2009-04-16 F. Hoffmann-La Roche Ag Quinolina-tiazolinonas con actividad antiproliferante cdk-1.
US7253285B2 (en) 2004-09-17 2007-08-07 Hoffmann-La Roche Inc. Thiazolinone 4-monosubstituted quinolines
TW200716132A (en) 2005-05-03 2007-05-01 Smithkline Beecham Corp Novel chemical compounds
EP1885362A4 (en) 2005-05-23 2010-09-22 Glaxosmithkline Llc NEW CHEMICAL COMPOUNDS
EP1888557A4 (en) 2005-06-08 2012-02-15 Glaxosmithkline Llc (5Z) -5- (6-QUINOXALINYLMETHYLIDENE) -2-Ý (2,4,6-trichlorophenyl) amino-1,3-thiazol-4 (5H) -one

Also Published As

Publication number Publication date
ZA200709813B (en) 2008-09-25
AP2007004241A0 (en) 2007-12-31
AR054059A1 (es) 2007-05-30
US20070179144A1 (en) 2007-08-02
EA200702457A1 (ru) 2008-04-28
TW200716580A (en) 2007-05-01
WO2006135712A2 (en) 2006-12-21
KR20080014017A (ko) 2008-02-13
CN101193863A (zh) 2008-06-04
WO2006135712A3 (en) 2007-06-28
JP2008543770A (ja) 2008-12-04
NZ563421A (en) 2010-07-30
BRPI0611096A2 (pt) 2010-12-21
PE20070083A1 (es) 2007-01-27
EP1888531A2 (en) 2008-02-20
CA2611480A1 (en) 2006-12-21
EP1888531A4 (en) 2009-06-17
MA29567B1 (fr) 2008-06-02
MX2007015572A (es) 2008-02-25
AU2006258032A1 (en) 2006-12-21
IL187423A0 (en) 2008-02-09
NO20080130L (no) 2008-01-08
US7674792B2 (en) 2010-03-09

Similar Documents

Publication Publication Date Title
CL2012000033A1 (es) Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer.
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
CR9772A (es) Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos
CL2007003540A1 (es) Compuestos derivados de macrociclos, inhibidores de la proteasa serina de hepatitis c; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
ATE479687T1 (de) Kinaseinhibitoren
ECSP099525A (es) Inhibidores de mek
CL2009000483A1 (es) Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
CL2007002234A1 (es) Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
NI200900170A (es) Derivados de isoindolina 4' - o - sustituidos y composiciones que los comprenden y métodos para usar los mismos.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
CL2008002998A1 (es) Compuestos derivados de piperazina-1-carboxamida, inhibidor de faah; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del dolor inflamatorio o neuropatico, ansiedad y depresion.
SV2007002397A (es) Aminopiridinas como inhibidores de b-secretasa ref. am101663
CL2011000933A1 (es) El compuesto 2-[(5-cloro-2-{[3-metil-1-(1-metiletil)-1h-pirazol-5-il]amino}-4-piridinil)amino]-n-(metiloxi)benzamida y sus sales, inhibidor de la quinasa de adhesion focal (fak); composicion farmaceutica que lo comprende; y su uso para el tratamiento del cancer.
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
ECSP088992A (es) Inhibidores de akt (proteina cinasa b)
NI201000047A (es) Uso de 3, 11b-cis-dihidrotetrabenzina en el tratamiento de la esclerosis múltiple y la mielitis autoinmunitaria.
CL2008002049A1 (es) Compuestos derivados de aminoindol macrociclicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
CL2008001990A1 (es) Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer.
CL2008001163A1 (es) Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.